Anti Cancer Tablets

• Composition: Ledipasvir and Sofosbuvir Tablets
• Brand: Hepcvir L
• Packing: 28 Tablet

• Product Description:
  We have marked a well-known position in this area by providing a broad range of Hepcivir L Tablet. Owing to high demand, we offer this product in diverse packing option that meet on client’s demand .
  HEPCVIR-L is a fixed-dose combination (FDC) of ledipasvir and sofosbuvir, which are direct-acting antiviral agents against the hepatitis C virus (HCV). Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.Hepcvir-L is the first once-a-day, fixed-dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients. Based on a generic version of Gilead Sciences Inc’s Harvoni tablets, Hepcvir-L will be sold in India at Rs 25,000 (~US$377) for a bottle of 28 tablets.
  Relative to fasting conditions, the administration of a single dose of ledipasvir -sofosbuvirFDC with a moderate fat (~600 kcal, 25% to 30% fat) or high fat (~1,000 kcal, 50% fat) meal increased sofosbuvir AUC0-inf by approximately 2-fold, but did not significantly affect sofosbuvir Cmax. The exposures of GS-331007 and ledipasvir were not altered in the presence of either meal type. The response rates in Phase 3 trials were similar in HCV-infected subjects who received ledipasvir -sofosbuvir FDC with food or without food. Ledipasvir-sofosbuvir FDC can be administered without regard to food.
  Excretion
  Following a single 90 mg oral dose of -ledipasvir, mean total recovery of the -radioactivity in feces and urine was approximately 87%, with most of the radioactive dose recovered from feces (approximately 86%). Unchanged ledipasvir excreted in feces accounted for a mean of 70% of the administered dose and the oxidative metabolite M19 accounted for 2.2% of the dose. These data indicate that biliary excretion of unchanged ledipasvir is a major route of elimination, with renal excretion being a minor pathway (approximately 1%). The median terminal half-life of ledipasvir following administration of ledipasvir and sofosbuvir FDC was 47 hours.

  Following a single 400 mg oral dose of -sofosbuvir, mean total recovery of the dose was greater than 92%, consisting of approximately 80%, 14% and 2.5% recovered in urine, feces and expired air, respectively. The majority of the sofosbuvir dose recovered in urine was GS-331007 (78%) while 3.5% was recovered as sofosbuvir. These data indicate that renal clearance is the major elimination pathway for GS-331007. The median terminal half-lives of sofosbuvir and GS-331007 following administration of ledipasvir-sofosbuvir FDC were 0.5 and 27 hours, respectively.
  Hepatic Impairment
  The pharmacokinetics of ledipasvir was studied with a single dose of 90 mg ledipasvir in HCV negative subjects with severe hepatic impairment (Child-Pugh Class C). Ledipasvir plasma exposure (AUC0-inf) was similar in subjects with severe hepatic impairment and control subjects with normal hepatic function. Population pharmacokinetics analysis in HCV-infected subjects indicated that cirrhosis had no clinically relevant effect on the exposure of ledipasvir.
  The pharmacokinetics of sofosbuvir wasstudied following 7-day dosing of 400 mg sofosbuvir in HCV-infected subjects with moderate and severe hepatic impairment (Child-Pugh Class B and C). Relative to subjects with normal hepatic function, the sofosbuvir AUC0-24 were 126% and 143% higher in moderate and severe hepatic impairment.

Specifications:

Composition: Abiraterone Acetate Tablets

Brand: Cipla

Strength: 250 mg

Packing: 120 Tablets

Description
Xbira 250 mg tablet belongs to a class drugs known as antiandrogens. It stops the body from making testosterone which can slow the growth of prostate cancer.XBIRA 250mg – Abiraterone Acetate is a drug used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant prostate cancer) which is a prostate cancer not responding to androgen deprivation or treatment with anti-androgens.Abiraterone Acetate decreased serum testosterone and other androgens in patients in the placebo-controlled Phase 3 clinical trials. It is not necessary to monitor the effect of Abiraterone Acetate on serum testosterone levels.
Changes in serum prostate-specific antigen (PSA) levels may be observed, but have not been shown to correlate with clinical benefit in individual patients.
Common side effects
Anemia, Joint pain, Joint swelling, Cough, Shortness of breath, Hot flashes, Increased cholesterol level in blood, Increased glucose level in blood, Increased triglyceride level in blood, Decreased potassium level in blood, Increased blood pressure, Urinary tract infection, Weakness, Vomiting, Diarrhoea
The recommended dose of XBIRA tablets is 1000mg (four 250mg tablets) administered orally once daily in combination with Prednisone 5mg administered orally twice daily. XBIRA tablets must be taken on an empty stomach. No food should be consumed for at least 2 hours before the dose of XBIRA tablets is taken and for at least 1 hour after the dose of XBIRA tablets is taken. The tablets should be swallowed whole with water and not to be crushed or chewed. It is highly advisable to administer the drug under strict medical supervision and advice.
Expert advice FOR XBIRA

Abiraterone acetate must be taken at least one hour before or two hours after eating and never with food.

Men who take abiraterone acetate should always use effective birth control measure when having physical relationship with a woman who is or may become pregnant.

You must inform your doctor or dentist that you take abiraterone acetate before receiving any medical or dental care, emergency care, or surgery.

Before you take abiraterone acetate tell your doctor if you have high blood sugar, swelling in the feet, ankles, or legs or any effects on your bones or have taken a medicine known as ketoconazole in the past for prostate cancer.

Contact your doctor if you experience any bone pain. An increased occurrence of bone fractures has been reported in patients using abiraterone acetate.

• Composition: Sorafenib Tosylate Tablets
• Brand: Natco
• Strength: 200 mg
• Packing: 120 Tablets

Description
Sorafenat is used for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer.
Sorafenat (sorafenib 200mg) is a cancer (chemotherapeutic) medication. Sorafenat (sorafenib 200mg) interferes with the growth of cancer cells and slows their growth and spread in the body.
Sorafenat (sorafenib 200mg) is used to treat a type of kidney cancer called advanced renal cell carcinoma. It is also used to treat liver cancer.
Sorafenat (sorafenib) is a cancer (chemotherapeutic) medication. Sorafenat interfere with the growth and spread of cancer cells in the body.
Sorafenat is used to treat a type of kidney cancer called advanced renal cell carcinoma. It is also used to treat liver cancer.
Sorafenat may also be used for purposes not listed in this medication guide.
Important information about Sorafenat
Do not use Sorafenat if you are pregnant. It could harm the unborn baby. Use effective birth control while you are using this medication and for at least 2 weeks after your treatment ends, whether you are a man or a woman. Sorafenat use by either parent may cause birth defects. Do not breast-feed while using this medication. You should not use Sorafenat if you are allergic to sorafenib, or if you have squamous cell lung cancer and you are being treated with carboplatin (Paraplatin) and paclitaxel (Onxol, Taxol, Abraxane).
Before you take Sorafenat, tell your doctor if you have kidney or liver problems (other than cancer), a bleeding or blood clotting disorder, heart disease, high blood pressure, heart disease, slow heartbeats, congestive heart failure, a personal or family history of Long QT syndrome, a history of stroke or heart attack, or any allergies.
Your blood pressure will need to be checked often. Visit your doctor regularly.
If you need surgery or dental work, tell the surgeon or dentist ahead of time that you are taking Sorafenat.
Sorafenat 200 mg tablet belongs to the class of drugs called multikinase inhibitors. It slows down the rate of growth of cancer cells by blocking the action of an abnormal protein that signals cancer cells to multiply. It cuts down the blood supply to the cancer cells and stops their growth and proliferation.It is better to take Sorafenat 200 mg tablet empty stomach (1 hour before food or 2 hours after food).
Avoid Sorafenat 200 mg tablet with high-fat meals such as olive oil, nuts & seeds (Brazil nuts), dark chocolate, butter and meat.
Expert advice FOR SORAFENAT

• Seek immediate medical attention if you experience chest pain, severe dizziness, fainting, sweating or shortness of breath, blood in your urine or stools, abnormal vaginal bleeding, severe stomach pain, coughing up blood, or any bleeding that will not stop while receiving treatment with Sorafenib.
• You may need frequent monitoring of fluid balance and electrolytes if you are at risk of renal dysfunction; monitoring of blood calcium levels and thyroid hormones if you are suffering from thyroid cancer.
• Tell your doctor if you are or planning to become pregnant or are breastfeeding, sorafenib may decrease fertility in men and women.
• Inform the doctor if you are suffering from high blood pressure, bleeding problems, chest pain, heart problems (prolongation of QT interval), kidney problems other than kidney cancer, or liver disease; if you are going to have a surgery or have been recently operated upon.